| Mrs Sarah Ann Lee, OD | |
|
4165 E Court St, Burton, MI 48509-1717 | |
| (810) 743-1276 | |
| (810) 743-2249 |
| Full Name | Mrs Sarah Ann Lee |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 30 Years |
| Location | 4165 E Court St, Burton, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306835640 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4901003706 (Michigan) | Primary |
| Provider Name | Sarah A. Lee P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1700902913 PECOS PAC ID: 2365532496 Enrollment ID: O20071213000240 |
News Archive
A large number of bacteria are present in human mouths and may pass into the blood when procedures such as the removal of a tooth are carried out. Chlorhexidine mouthwashes have a powerful antimicrobial effect, but there are opposing positions on its use in these cases.
Prana Biotechnology Limited has announced that it entered into definitive agreements with new institutional investors for the purchase of US$20 million of securities through the sale of 4 million ADR's at US$5.00 per ADR.
A new technique successfully used in mice to identify embryos likely to result in a successful pregnancy could be used in humans, potentially boosting IVF success rates and helping to reduce the number of multiple births, according to Cardiff University scientists.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Sarah Ann Lee, OD 4165 E Court St, Burton, MI 48509-1717 Ph: (810) 743-1276 | Mrs Sarah Ann Lee, OD 4165 E Court St, Burton, MI 48509-1717 Ph: (810) 743-1276 |
News Archive
A large number of bacteria are present in human mouths and may pass into the blood when procedures such as the removal of a tooth are carried out. Chlorhexidine mouthwashes have a powerful antimicrobial effect, but there are opposing positions on its use in these cases.
Prana Biotechnology Limited has announced that it entered into definitive agreements with new institutional investors for the purchase of US$20 million of securities through the sale of 4 million ADR's at US$5.00 per ADR.
A new technique successfully used in mice to identify embryos likely to result in a successful pregnancy could be used in humans, potentially boosting IVF success rates and helping to reduce the number of multiple births, according to Cardiff University scientists.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
› Verified 5 days ago
Dr. Jonathon David Connors, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1235 S Center Rd Ste 16, Burton, MI 48509 Phone: 810-744-1950 Fax: 810-744-1515 | |
General Optical Company Optometrist Medicare: Medicare Enrolled Practice Location: 1235 S Center Rd, Suite 16, Burton, MI 48509 Phone: 810-744-1950 Fax: 810-744-1515 | |
Dr Todd W Lee O D P C Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5323 E Court St N, Burton, MI 48509 Phone: 810-744-9596 | |
Dr. Mark D. Engelman, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 3385 S Center Rd, Burton, MI 48519 Phone: 810-244-3434 Fax: 810-715-0301 | |
Christopher Kowalski, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1235 S Center Rd, Suite 16, Burton, MI 48509 Phone: 810-744-1950 | |
Casey L Coulter, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4165 E Court St, Burton, MI 48509 Phone: 810-743-1267 | |
Ross H Williams, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4067 E Court St, Suite 10, Burton, MI 48509 Phone: 810-230-1600 Fax: 810-715-2021 |